U.S. markets closed

CareDx, Inc (CDNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
79.08-0.18 (-0.23%)
At close: 4:00PM EST

CareDx, Inc

1 Tower Place
9th Floor
South San Francisco, CA 94080
United States
415 287 2300
http://www.caredx.com

Sector(s)Healthcare
IndustryDiagnostics & Research
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter MaagExec. Chairman1.08M1.58M1967
Dr. Reginald SeetoPres, CEO & Director826kN/A1972
Ms. Sasha King M.B.A.Chief Marketing Officer509.2k1.13M1986
Mr. Marcel KonradInterim Chief Financial OfficerN/AN/A1975
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CareDx, Inc. discovers, develops, and commercializes healthcare solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; and AlloMap Heart, a gene expression solution for heart transplant patients. The company also develops, manufactures, markets, and sells products that increase the chance of successful transplants by facilitating a match between a donor and a recipient of stem cells and solid organs. In addition, it offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of HLA alleles; QTYPE that enables precision in HLA typing at a low to intermediate resolution for samples that uses real-time polymerase chain reaction methodology; and TruSight HLA, a solution for use in transplantation diagnostic testing. Further, the company provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Ottr, a transplant patient tracking software; and XynQAPI and Waitlist Management solutions. It offers its products directly to customers, as well as through third-party distributors. The company has a license agreement with Illumina, Inc. for the development, commercialization, and distribution of sequencing product line for use in transplantation diagnostic testing; and Cibiltech SAS to commercialize KidneyCare iBox, a software for the predictive analysis of post-transplantation kidney allograft loss, as well as a partnership with IDbyDNA, Inc. for the development of metagenomic infectious disease testing. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. CareDx, Inc. was incorporated in 1998 and is headquartered in South San Francisco, California.

Corporate Governance

CareDx, Inc’s ISS Governance QualityScore as of December 2, 2020 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 9; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.